>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

SB 216763

SB 216763是有效，选择性和ATP竞争性的 GSK-3 抑制剂，抑制GSK-3α和GSK-3β的 IC50 为34.3 nM。

货号：
TK0504
规格：

1mg

5mg

10mg

50mg
价格：
￥0.00

产品参数

CAS No.	280744-09-4
生物活性	SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC50s of 34.3 nM for both GSK-3α and GSK-3β.
分子式	C19H12Cl2N2O2
分子量	371.22
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : 100 mg/mL (269.38 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble)
体内研究	SB216763 (20 mg/kg, i.v.) significantly improves the survival of BLM-treated mice. Mice randomized to receive BLM plus SB216763 shows a noteworthy reduction, compared with BLM-treated mice. SB216763 (20 mg/kg, i.v.) reduces the magnitude of BLM-induced alveolitis. SB 216763 (0.2 mg/kg, i.v.) with either 17β-E100 or Geni100 reverses the ceiling effect because these agents significantly reduce infarct size when the rabbits' hearts are submitted to 30-min CAO.
体外研究	SB-216763 (10-20 µM) induces β-catenin mediated-transcription in a dose-dependent manner in HEK293 cells. SB-216763 (10, 15 and 20 µM) can maintain mESCs with a pluripotent-like morphology in long-term culture. SB-216763 (10 µM) can maintain J1 mESCs in a pluripotent state for more than a month. SB-216763 inhibits GSK-3 with IC50 of 34 nM. SB-216763 is equally effective at inhibiting human GSK-3α and GSK-3β.
文献	•Theranostics. 2019 Aug 12;9(20):5769-5783. •Haematologica. 2020 Mar;105(3):661-673. •Biomed Pharmacother. 2019 Dec;120:109231. •Biochem Pharmacol. 2018 Apr;150:280-292. •Life Sci. 2020 Sep 1;256:117983. •J Mol Cell Cardiol. 2020 Dec;149:82-94. •J Cell Biochem. 2018 Jul;119(7):5934-5943. •Toxicol Appl Pharmacol. 2020 Jan 1;386:114813. •Toxicol Appl Pharmacol. 2016 Dec 15;313:195-203. •Biochem Biophys Res Commun. 2020 May 14;525(4):1074-1080. •Evid Based Complement Alternat Med. 2019 May 30;2019:9692350. •Harvard Medical School LINCS LIBRARY
纯度及产品资料	98%

推荐产品